Korean J Hematol 2012; 47(4): 241-242  https://doi.org/10.5045/kjh.2012.47.4.241
Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
Chul Won Jung, M.D. Ph.D.

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Published online: December 24, 2012.
© The Korean Journal of Hematology. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


e-submission

This Article

Current Issue

ba_link01

Indexed/Covered by

Today : 56  /
Total : 227,014